Skip to content

Support improves hepatitis C treatment completion and response rates among drug users

Adherence to hepatitis C treatment: unravelling the complexities

Telaprevir twice-daily works as well as every eight hours, safe for hepatitis C patients with cirrhosis

Which patients should be prioritised for new hepatitis C treatments?

Low viral load in hepatitis C treatment: Is a third drug necessary?

Antiviral treatment reduces risk of liver cancer in people with hepatitis C-related cirrhosis and fibrosis

Vitamin D deficiency associated with a poorer response to HCV treatment in HIV/HCV-co-infected patients

Higher levels of adherence to hepatitis C therapy improve treatment outcomes in people with hepatitis C and HIV

No evidence of an interaction between abacavir and ribavirin